Scilex Holding Company (SCLXW)

Market Cap	43.25M
Revenue (ttm)	55.15M
Net Income (ttm)	-87.75M
Shares Out	183.24M
EPS (ttm)	-0.78
PE Ratio	n/a
Forward PE	0.18
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,005
Open	0.084
Previous Close	0.084
Day's Range	0.084 - 0.100
52-Week Range	0.084 - 0.100
Beta	1.07
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 7, 2025

About SCLXW

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of ...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• CEO: Jaisim Shah
• Employees: 105
• Stock Exchange: NASDAQ
• Ticker Symbol: SCLXW
• Website: https://www.scilexholding.com

Financial Performance

In 2023, Scilex Holding Company's revenue was $46.74 million, an increase of 22.90% compared to the previous year's $38.03 million. Losses were -$166.98 million, 614.7% more than in 2022.